Grey Horizon postings will resume week of January 5, 2026.

 To all Grey Horizon readers, 

Thank you for your continued support of this blog.  Postings will resume the week of January 5, 2026. 

Season's Greetings and all the best for the new year.  

Neoadjuvant immunotherapy and understanding anticancer immunity

 Study results currently being presented at the ESMO Immuno-Oncology Congress (held in London, England, December 10-12, 2025) showcase the rise of neoadjuvant immunotherapy studies "from small investigator-led window-of-opportunity...to standard of care paradigms across various tumour types."  Using triple-negative breast cancer and early-stage non-small cell lung cancer as examples, treating patients before surgery provides "access to living tumour ecosystems responding - or not- to immunotherapy." 

Click here to read more and note the Immuno-Oncology Congress program details below: 

Mulder K, et al. Residual tumour immune microenvironment shapes relapse risk in early TNBC following immunotherapy. ESMO Immuno-Oncology Congress 2025 - Abstract 328MO

Nijman H, et al. Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer. ESMO Immuno-Oncology Congress 2025 - Abstract 329MO

Pircher A, et al. Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME): Clinical results including multi-omic deconvolution of the TME from the INNWOP01 study. ESMO Immuno-Oncology Congress 2025 - LBA1

Going beyond protocol is key for young people with cancer

 Recently, at the ESMO Asia Congress 2025, emphasis was placed on the diagnosis of cancer in adolescents and young adults (AYA), which "varies considerably by age, sex, and socioeconomic status." While Western countries are increasingly dedicating research pursuits to AYA cancer care, "countries with low and low-middle sociodemographic indices" carry high AYA cancer burden. 

Click here to learn more: